<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04015804</url>
  </required_header>
  <id_info>
    <org_study_id>ICM-BDD 2015/05</org_study_id>
    <nct_id>NCT04015804</nct_id>
  </id_info>
  <brief_title>Robotic Low Rectum Anterior Resection</brief_title>
  <acronym>GROG-R01</acronym>
  <official_title>European Ambispective Cohort of Rectal Cancer Patient Who Underwent Robotic Low Anterior Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut du Cancer de Montpellier - Val d'Aurelle</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The laparoscopic approach for total mesorectal excision (L-TME) results improved short-term
      outcomes. However this approach has technical limitations when the pelvis is narrow and deep.
      Indeed there is a limited mobility of straight laparoscopic instruments and associated loss
      of dexterity, unstable camera view and compromised ergonomics for the surgeon. Robotic
      technology was developed to reduce these limitations and offers the advantages of intuitive
      manipulation of laparoscopic instruments with wrist articulation, a 3-dimensional field of
      view, a stable camera platform with zoom magnification, dexterity enhancement and an
      ergonomic operating environment. A major advantage of the robotic approach is the surgeon's
      simultaneous control of the camera and of the two or three additional instruments. This
      advantage facilitates traction and counter-traction. The technological advantages of robotic
      surgery should also allow a finer dissection in a narrow pelvic cavity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The laparoscopic approach for laparoscopic total mesorectal excision (L-TME) results improved
      short-term outcomes and provides a clearer intraoperative view compared with the open
      approach in a deep and narrow pelvis. Preliminary results from the COLOR II trial confirmed
      improved patient recovery and similar safety, same resection margins and completeness of
      resection using L-TME compared with the results achieved with open surgery.Results from the
      CLASICC trial supported the use of laparoscopic surgery for colorectal cancer and showed no
      difference between laparoscopically-assisted TME and conventional open resection at 10 years
      post-procedure in terms of overall survival, disease-free survival and local recurrence.

      Despite these positive clinical outcomes for L-TME, laparoscopic resection of rectal cancer,
      especially in a deep and narrow pelvis, is technically demanding and demands a long learning
      curve. Technical limitations include limited mobility of straight laparoscopic instruments
      and associated loss of dexterity, unstable camera view and compromised ergonomics for the
      surgeon. These limitations could explain the conversion rate which remained at 17% in the
      last COLOR II trial.2 In order to avoid this drawback, we have described for patients with
      high-risk of conversion, the trans-anal endoscopic proctectomy (TAEP) approach performed with
      the Transanal Endoscopic Operation (TEO) device.This trans-anal procedure is also called
      trans anal minimally invasive surgery (TAMIS) if a laparoscopic port is used.

      Robotic technology was developed to reduce these limitations and offers the advantages of
      intuitive manipulation of laparoscopic instruments with wrist articulation, a 3-dimensional
      field of view, a stable camera platform with zoom magnification, dexterity enhancement and an
      ergonomic operating environment. A major advantage of the robotic approach is the surgeon's
      simultaneous control of the camera and of the two or three additional instruments. This
      advantage facilitates traction and counter-traction. The technological advantages of robotic
      surgery should also allow a finer dissection in a narrow pelvic cavity. However, total
      robotic surgery for rectal cancer is still technically challenging and involves two operative
      fields (splenic flexure and rectum), potential collision of the robotic arms and lack of
      tactile feedback.

      Reports of robotic and laparoscopic rectal cancer surgery outcomes showed similar
      intraoperative results and morbidity, postoperative recovery and short-term oncologic
      outcomes.However, longer operation times have been described as a disadvantage of the robotic
      system, compared with conventional laparoscopy. On the other hand, all meta-analyses
      comparing robotic total mesorectal excision (R-TME) and L-TME concluded in reduction of the
      conversion rate.

      Since 2007, the rectal surgery with robotic assistance is booming. To date, seven
      meta-analyzes have been published. All show that the robot exceeds laparoscopy to reduce the
      conversion rate. The last two meta-analyzes that had gathered more than 800 patients
      undergoing robotic surgery have again highlighted the contribution of the robot to secure the
      radial margin and decrease sexual sequelae. However, there is not so far from Phase 3
      randomized trial dealing with the subject. The ROLARR protocol was completed in late 2014 (Ph
      III laparoscopy / Robot), the first results are published in late 2015.

      The interest of a European multicenter ambispective (retrospective and prospective) database
      is fundamental because this early work suggests that the robot can make more for specific
      subgroups of patients, particularly in high surgical risk patients (Male, narrow pelvis, high
      BMI, mesorectal fat, large tumor of the anterior and middle third).

      The largest series of R-TME stems from the US national cancer database (965 patients operated
      by R-TME) and confirms a 9.5% conversion rate compared to 16.4% with L-TME (p &lt; 0.001).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Conversion rate for robotic surgery</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anatomo-pathological curability criteria</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median of hospitalization time</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative morbidity</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of robot docking</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operating time</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Rectum Cancer</condition>
  <arm_group>
    <arm_group_label>Clinical database</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical database</intervention_name>
    <description>Creation of an ambispective (retrospective and prospective), multicentric and European clinical database for surgery with robotic assistance in rectal cancers with implementation in France and then in Europe</description>
    <arm_group_label>Clinical database</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men or women ≥ 18 years

          2. Introducing rectal cancer, colorectal junction eligible to robotic surgery support
             from June 2015

          3. Treatment Naive for this cancer

          4. Enjoying a social protection scheme (For France only)

          5. Patient followed in the participant center

        Exclusion Criteria:

          1. Male or female age (s) under 18 years

          2. Private person of liberty or under supervision (including guardianship)

          3. People who do not speak French (For France only)

          4. Major Nobody unable to consent

          5. Patient GROG-R01 already included in the base

          6. Patient Refusal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Rouanet, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut régional du cancer de Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Pierre Bleuse, MD</last_name>
    <phone>4 67 61 31 02</phone>
    <phone_ext>+33</phone_ext>
    <email>jean-pierre.bleuse@icm.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCL</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Kharteuse, MD</last_name>
      <email>alex.kartheuser@uclouvain.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen</name>
      <address>
        <city>Marseille</city>
        <state>Bouches Du Rhône</state>
        <zip>13003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Régis Fara, MD</last_name>
      <phone>4 13 427 240</phone>
      <phone_ext>+33</phone_ext>
      <email>regis.fara@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <state>Bouches Du Rhône</state>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard Lelong, MD</last_name>
      <phone>4 91 22 33 33</phone>
      <phone_ext>+33</phone_ext>
      <email>lelongb@ipc.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <state>Calvados</state>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel Polycarpe, MD</last_name>
      <phone>2 31 45 55 07</phone>
      <phone_ext>+33</phone_ext>
      <email>e.polycarpe@baclesse.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Kennedy</name>
      <address>
        <city>Nîmes</city>
        <state>Gard</state>
        <zip>30900</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Amielh, MD</last_name>
      <phone>4 66 62 27 72</phone>
      <phone_ext>+33</phone_ext>
      <email>nemaudig@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Jean du Languedoc</name>
      <address>
        <city>Toulouse</city>
        <state>Haute Garonne</state>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnault Béliard, MD</last_name>
      <phone>5 61 54 95 84</phone>
      <phone_ext>+33</phone_ext>
      <email>abeliard@capio.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Dupuytren</name>
      <address>
        <city>Limoges</city>
        <state>Haute Vienne</state>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muriel Mathonnet, MD</last_name>
      <email>muriel.mathonnet@chu-limoges.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital privé d'Anthony</name>
      <address>
        <city>Antony</city>
        <state>Hauts De Seine</state>
        <zip>92160</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marc Thillois, MD</last_name>
      <phone>1 46 74 41 62</phone>
      <phone_ext>+33</phone_ext>
      <email>docteur.thillois@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut régional du cancer de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <state>Hérault</state>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Rouanet, MD</last_name>
      <phone>4 67 61 30 71</phone>
      <phone_ext>+33</phone_ext>
      <email>philippe.rouanet@icm.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Michalon</name>
      <address>
        <city>Grenoble</city>
        <state>Isère</state>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Luc Faucheron, MD</last_name>
      <email>jlfaucheron@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <state>Loire Atlantique</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume Meurette, MD</last_name>
      <phone>2 40 08 30 22</phone>
      <phone_ext>+33</phone_ext>
      <email>guillaume.meurette@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest</name>
      <address>
        <city>Saint-Herblain</city>
        <state>Loire Atlantique</state>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric Dumont, MD</last_name>
      <email>frederic.dumont@ico.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHR Orléans</name>
      <address>
        <city>Orléans</city>
        <state>Loiret</state>
        <zip>45100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnaud Piquard, MD</last_name>
      <email>arnaud.piquard@chr-orleans.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <state>Lorraine</state>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Bresler, MD</last_name>
      <phone>3 83 15 31 10</phone>
      <phone_ext>+33</phone_ext>
      <email>l.bresler@chu-nancy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Oscart Lambret</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehrdad Jafari, MD</last_name>
      <email>m-jafari@o-lambret.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Val De Marne</state>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonor Benhaim, MD</last_name>
      <email>goere@igr.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Diaconesses</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain Valverde, MD</last_name>
      <email>avalverde@hopital-dcss.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Douard, MD</last_name>
      <phone>1 56 09 30 22</phone>
      <phone_ext>+33</phone_ext>
      <email>richard.douard@egp.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier-Princesse Grace</name>
      <address>
        <city>Monaco</city>
        <zip>98012</zip>
        <country>Monaco</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hubert Perrin, MD</last_name>
      <email>hperrin@chpg.mc</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Monaco</country>
  </location_countries>
  <link>
    <url>http://onlinelibrary.wiley.com.gate1.inist.fr/doi/10.1002/14651858.CD005200.pub3/abstract</url>
    <description>Laparoscopic versus open total mesorectal excision for rectal cancer. In: Cochrane Database of Systematic Reviews</description>
  </link>
  <reference>
    <citation>Green BL, Marshall HC, Collinson F, Quirke P, Guillou P, Jayne DG, Brown JM. Long-term follow-up of the Medical Research Council CLASICC trial of conventional versus laparoscopically assisted resection in colorectal cancer. Br J Surg. 2013 Jan;100(1):75-82. doi: 10.1002/bjs.8945. Epub 2012 Nov 6.</citation>
    <PMID>23132548</PMID>
  </reference>
  <reference>
    <citation>van der Pas MH, Haglind E, Cuesta MA, Fürst A, Lacy AM, Hop WC, Bonjer HJ; COlorectal cancer Laparoscopic or Open Resection II (COLOR II) Study Group. Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial. Lancet Oncol. 2013 Mar;14(3):210-8. doi: 10.1016/S1470-2045(13)70016-0. Epub 2013 Feb 6.</citation>
    <PMID>23395398</PMID>
  </reference>
  <reference>
    <citation>Rouanet P, Mourregot A, Azar CC, Carrere S, Gutowski M, Quenet F, Saint-Aubert B, Colombo PE. Transanal endoscopic proctectomy: an innovative procedure for difficult resection of rectal tumors in men with narrow pelvis. Dis Colon Rectum. 2013 Apr;56(4):408-15. doi: 10.1097/DCR.0b013e3182756fa0.</citation>
    <PMID>23478607</PMID>
  </reference>
  <reference>
    <citation>Fernández-Hevia M, Delgado S, Castells A, Tasende M, Momblan D, Díaz del Gobbo G, DeLacy B, Balust J, Lacy AM. Transanal total mesorectal excision in rectal cancer: short-term outcomes in comparison with laparoscopic surgery. Ann Surg. 2015 Feb;261(2):221-7. doi: 10.1097/SLA.0000000000000865.</citation>
    <PMID>25185463</PMID>
  </reference>
  <reference>
    <citation>Sylla P, Rattner DW, Delgado S, Lacy AM. NOTES transanal rectal cancer resection using transanal endoscopic microsurgery and laparoscopic assistance. Surg Endosc. 2010 May;24(5):1205-10. doi: 10.1007/s00464-010-0965-6. Epub 2010 Feb 26.</citation>
    <PMID>20186432</PMID>
  </reference>
  <reference>
    <citation>Atallah S, Martin-Perez B, Albert M, deBeche-Adams T, Nassif G, Hunter L, Larach S. Transanal minimally invasive surgery for total mesorectal excision (TAMIS-TME): results and experience with the first 20 patients undergoing curative-intent rectal cancer surgery at a single institution. Tech Coloproctol. 2014 May;18(5):473-80. doi: 10.1007/s10151-013-1095-7. Epub 2013 Nov 23.</citation>
    <PMID>24272607</PMID>
  </reference>
  <reference>
    <citation>D'Annibale A, Pernazza G, Monsellato I, Pende V, Lucandri G, Mazzocchi P, Alfano G. Total mesorectal excision: a comparison of oncological and functional outcomes between robotic and laparoscopic surgery for rectal cancer. Surg Endosc. 2013 Jun;27(6):1887-95. doi: 10.1007/s00464-012-2731-4. Epub 2013 Jan 5.</citation>
    <PMID>23292566</PMID>
  </reference>
  <reference>
    <citation>Kwak JM, Kim SH, Kim J, Son DN, Baek SJ, Cho JS. Robotic vs laparoscopic resection of rectal cancer: short-term outcomes of a case-control study. Dis Colon Rectum. 2011 Feb;54(2):151-6. doi: 10.1007/DCR.0b013e3181fec4fd.</citation>
    <PMID>21228661</PMID>
  </reference>
  <reference>
    <citation>Park JS, Choi GS, Lim KH, Jang YS, Jun SH. Robotic-assisted versus laparoscopic surgery for low rectal cancer: case-matched analysis of short-term outcomes. Ann Surg Oncol. 2010 Dec;17(12):3195-202. doi: 10.1245/s10434-010-1162-5. Epub 2010 Jun 30.</citation>
    <PMID>20589436</PMID>
  </reference>
  <reference>
    <citation>Patel CB, Ragupathi M, Ramos-Valadez DI, Haas EM. A three-arm (laparoscopic, hand-assisted, and robotic) matched-case analysis of intraoperative and postoperative outcomes in minimally invasive colorectal surgery. Dis Colon Rectum. 2011 Feb;54(2):144-50. doi: 10.1007/DCR.0b013e3181fec377.</citation>
    <PMID>21228660</PMID>
  </reference>
  <reference>
    <citation>Bianchi PP, Ceriani C, Locatelli A, Spinoglio G, Zampino MG, Sonzogni A, Crosta C, Andreoni B. Robotic versus laparoscopic total mesorectal excision for rectal cancer: a comparative analysis of oncological safety and short-term outcomes. Surg Endosc. 2010 Nov;24(11):2888-94. doi: 10.1007/s00464-010-1134-7. Epub 2010 Jun 5.</citation>
    <PMID>20526623</PMID>
  </reference>
  <reference>
    <citation>Popescu I, Vasilescu C, Tomulescu V, Vasile S, Sgarbura O. The minimally invasive approach, laparoscopic and robotic, in rectal resection for cancer. A single center experience. Acta Chir Iugosl. 2010;57(3):29-35.</citation>
    <PMID>21066980</PMID>
  </reference>
  <reference>
    <citation>Lin S, Jiang HG, Chen ZH, Zhou SY, Liu XS, Yu JR. Meta-analysis of robotic and laparoscopic surgery for treatment of rectal cancer. World J Gastroenterol. 2011 Dec 21;17(47):5214-20. doi: 10.3748/wjg.v17.i47.5214.</citation>
    <PMID>22215947</PMID>
  </reference>
  <reference>
    <citation>Trastulli S, Farinella E, Cirocchi R, Cavaliere D, Avenia N, Sciannameo F, Gullà N, Noya G, Boselli C. Robotic resection compared with laparoscopic rectal resection for cancer: systematic review and meta-analysis of short-term outcome. Colorectal Dis. 2012 Apr;14(4):e134-56. doi: 10.1111/j.1463-1318.2011.02907.x. Review.</citation>
    <PMID>22151033</PMID>
  </reference>
  <reference>
    <citation>Memon S, Heriot AG, Murphy DG, Bressel M, Lynch AC. Robotic versus laparoscopic proctectomy for rectal cancer: a meta-analysis. Ann Surg Oncol. 2012 Jul;19(7):2095-101. doi: 10.1245/s10434-012-2270-1. Epub 2012 Feb 16.</citation>
    <PMID>22350601</PMID>
  </reference>
  <reference>
    <citation>Yang Y, Wang F, Zhang P, Shi C, Zou Y, Qin H, Ma Y. Robot-assisted versus conventional laparoscopic surgery for colorectal disease, focusing on rectal cancer: a meta-analysis. Ann Surg Oncol. 2012 Nov;19(12):3727-36. doi: 10.1245/s10434-012-2429-9. Epub 2012 Jul 3.</citation>
    <PMID>22752371</PMID>
  </reference>
  <reference>
    <citation>González Fernández AM, Mascareñas González JF. [Total laparoscopic mesorectal excision versus robot-assisted in the treatment of rectal cancer: a meta-analysis]. Cir Esp. 2012 Jun-Jul;90(6):348-54. doi: 10.1016/j.ciresp.2012.03.004. Epub 2012 Apr 24. Spanish.</citation>
    <PMID>22537895</PMID>
  </reference>
  <reference>
    <citation>Ortiz-Oshiro E, Sánchez-Egido I, Moreno-Sierra J, Pérez CF, Díaz JS, Fernández-Represa JÁ. Robotic assistance may reduce conversion to open in rectal carcinoma laparoscopic surgery: systematic review and meta-analysis. Int J Med Robot. 2012 Sep;8(3):360-70. doi: 10.1002/rcs.1426. Epub 2012 Mar 22. Review.</citation>
    <PMID>22438060</PMID>
  </reference>
  <reference>
    <citation>Xiong B, Ma L, Zhang C, Cheng Y. Robotic versus laparoscopic total mesorectal excision for rectal cancer: a meta-analysis. J Surg Res. 2014 May 15;188(2):404-14. doi: 10.1016/j.jss.2014.01.027. Epub 2014 Jan 22.</citation>
    <PMID>24565506</PMID>
  </reference>
  <reference>
    <citation>Son GM, Kim JG, Lee JC, Suh YJ, Cho HM, Lee YS, Lee IK, Chun CS. Multidimensional analysis of the learning curve for laparoscopic rectal cancer surgery. J Laparoendosc Adv Surg Tech A. 2010 Sep;20(7):609-17. doi: 10.1089/lap.2010.0007.</citation>
    <PMID>20701545</PMID>
  </reference>
  <reference>
    <citation>Kim HJ, Choi GS, Park JS, Park SY. Multidimensional analysis of the learning curve for robotic total mesorectal excision for rectal cancer: lessons from a single surgeon's experience. Dis Colon Rectum. 2014 Sep;57(9):1066-74. doi: 10.1097/DCR.0000000000000174.</citation>
    <PMID>25101602</PMID>
  </reference>
  <reference>
    <citation>Jiménez-Rodríguez RM, Díaz-Pavón JM, de la Portilla de Juan F, Prendes-Sillero E, Dussort HC, Padillo J. Learning curve for robotic-assisted laparoscopic rectal cancer surgery. Int J Colorectal Dis. 2013 Jun;28(6):815-21. doi: 10.1007/s00384-012-1620-6. Epub 2012 Dec 15.</citation>
    <PMID>23242270</PMID>
  </reference>
  <reference>
    <citation>Kuo LJ, Lin YK, Chang CC, Tai CJ, Chiou JF, Chang YJ. Clinical outcomes of robot-assisted intersphincteric resection for low rectal cancer: comparison with conventional laparoscopy and multifactorial analysis of the learning curve for robotic surgery. Int J Colorectal Dis. 2014 May;29(5):555-62. doi: 10.1007/s00384-014-1841-y. Epub 2014 Feb 23.</citation>
    <PMID>24562546</PMID>
  </reference>
  <reference>
    <citation>Baek JH, Pastor C, Pigazzi A. Robotic and laparoscopic total mesorectal excision for rectal cancer: a case-matched study. Surg Endosc. 2011 Feb;25(2):521-5. doi: 10.1007/s00464-010-1204-x. Epub 2010 Jul 7.</citation>
    <PMID>20607559</PMID>
  </reference>
  <reference>
    <citation>Park YA, Kim JM, Kim SA, Min BS, Kim NK, Sohn SK, Lee KY. Totally robotic surgery for rectal cancer: from splenic flexure to pelvic floor in one setup. Surg Endosc. 2010 Mar;24(3):715-20. doi: 10.1007/s00464-009-0656-3. Epub 2009 Aug 18.</citation>
    <PMID>19688388</PMID>
  </reference>
  <reference>
    <citation>Speicher PJ, Englum BR, Ganapathi AM, Nussbaum DP, Mantyh CR, Migaly J. Robotic Low Anterior Resection for Rectal Cancer: A National Perspective on Short-term Oncologic Outcomes. Ann Surg. 2015 Dec;262(6):1040-5. doi: 10.1097/SLA.0000000000001017.</citation>
    <PMID>25405559</PMID>
  </reference>
  <reference>
    <citation>Tuech JJ, Karoui M, Lelong B, De Chaisemartin C, Bridoux V, Manceau G, Delpero JR, Hanoun L, Michot F. A step toward NOTES total mesorectal excision for rectal cancer: endoscopic transanal proctectomy. Ann Surg. 2015 Feb;261(2):228-33. doi: 10.1097/SLA.0000000000000994.</citation>
    <PMID>25361216</PMID>
  </reference>
  <reference>
    <citation>Wolthuis AM, de Buck van Overstraeten A, D'Hoore A. Dynamic article: transanal rectal excision: a pilot study. Dis Colon Rectum. 2014 Jan;57(1):105-9. doi: 10.1097/DCR.0000000000000008.</citation>
    <PMID>24316953</PMID>
  </reference>
  <reference>
    <citation>Dumont F, Goéré D, Honoré C, Elias D. Transanal endoscopic total mesorectal excision combined with single-port laparoscopy. Dis Colon Rectum. 2012 Sep;55(9):996-1001. doi: 10.1097/DCR.0b013e318260d3a0.</citation>
    <PMID>22874608</PMID>
  </reference>
  <reference>
    <citation>Zorron R, Phillips HN, Coelho D, Flach L, Lemos FB, Vassallo RC. Perirectal NOTES access: &quot;down-to-up&quot; total mesorectal excision for rectal cancer. Surg Innov. 2012 Mar;19(1):11-9. doi: 10.1177/1553350611409956. Epub 2011 Jul 7.</citation>
    <PMID>21742663</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 4, 2019</study_first_submitted>
  <study_first_submitted_qc>July 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2019</study_first_posted>
  <last_update_submitted>July 10, 2019</last_update_submitted>
  <last_update_submitted_qc>July 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>rectum</keyword>
  <keyword>robot</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

